Dermatomyositis
Dermatomyositis (DM) is a systemic autoimmune disorder characterized by distinctive cutaneous manifestations and inflammatory myopathy. It affects both adults and children, with a female predominance (approximately 2:1) and a bimodal age distribution peaking in childhood (5–15 years) and adulthood (40–60 years). The estimated incidence is 1–10 per million person-years. Unlike other inflammatory myopathies, the pathogenesis of DM centers on type I interferon-driven innate immunity and complement-mediated microangiopathy targeting intramuscular capillaries, rather than direct T-cell attack on muscle fibers. The identification of five myositis-specific antibodies (MSAs) has transformed the approach to DM, enabling antibody-defined clinical phenotyping that guides cancer screening, predicts organ involvement, informs prognosis, and increasingly directs therapeutic decisions.
Bottom Line
- Pathophysiology: Complement-mediated microangiopathy and type I interferon pathway activation cause perifascicular muscle fiber atrophy; membrane attack complex (C5b-9) deposition on capillaries is an early and relatively specific finding; autoantibody internalization into muscle may directly disrupt target protein function
- Skin findings are the hallmark: Heliotrope rash (violaceous periorbital discoloration), Gottron papules (erythematous papules over knuckles), V-sign, shawl sign, holster sign, mechanic’s hands, and periungual telangiectasia; skin changes may precede, accompany, or rarely be absent from myopathy
- Antibody-defined phenotypes: Anti-Mi-2 (classic DM, treatment-responsive); anti-TIF1-γ (highest cancer risk); anti-NXP-2 (calcinosis, cancer risk); anti-MDA5 (rapidly progressive ILD, minimal myopathy); anti-SAE (skin-predominant onset, evolving weakness)
- Cancer association: Present in 15–30% of adult DM; highest risk with anti-TIF1-γ (up to 60–80% in patients >40 years); IMACS 2023 guidelines stratify patients into standard, moderate, and high cancer risk categories
- Treatment: IVIg has FDA-label indication for DM (ProDERM trial); corticosteroids remain first-line; steroid-sparing agents include methotrexate, azathioprine, mycophenolate; rituximab for refractory disease; JAK inhibitors and CAR T-cell therapy are emerging options
- Anti-MDA5 emergency: Rapidly progressive ILD carries >50% mortality without early aggressive triple immunosuppression (corticosteroids + calcineurin inhibitor + cyclophosphamide)
Epidemiology
DM has an estimated incidence of 1–10 per million person-years and a prevalence of approximately 10–20 per 100,000. Women are affected roughly twice as often as men. Two age peaks are recognized: juvenile DM (JDM) typically presents between ages 5 and 15 years, while adult DM peaks between ages 40 and 60 years. Certain MSA subtypes show distinct demographic patterns—anti-Mi-2 is more common in younger adults, anti-TIF1-γ predominates in older patients with higher cancer risk, and anti-MDA5 has a higher prevalence in East Asian populations. Skin findings may be subtle or delayed in patients with darker skin tones, contributing to diagnostic delays and health disparities.
Pathophysiology
Complement-Mediated Microangiopathy
The central pathologic mechanism in DM involves activation of the complement cascade with deposition of the membrane attack complex (C5b-9) on endomysial capillaries. This leads to capillary injury, endothelial swelling, microvascular thrombosis, and progressive capillary loss. The resulting ischemia produces the characteristic perifascicular atrophy seen on muscle biopsy. Ultrastructural studies demonstrate tubuloreticular inclusions within endothelial cells—structures composed of interferon-inducible proteins that are considered a morphologic hallmark of DM.
Type I Interferon Pathway
DM is fundamentally an interferon-mediated disease. Key evidence includes:
- Upregulation of type I interferon (IFN-I)-stimulated genes and proteins, particularly myxovirus resistance protein A (MxA) and interferon-stimulated gene 15 (ISG15), concentrated in the perifascicular region
- Increased plasmacytoid dendritic cells (a major IFN-I source) in DM muscle tissue
- Correlation of IFN-I gene expression levels in blood with disease activity
- Toxic effects of IFN-I on muscle stem cell proliferation, potentially contributing to impaired muscle regeneration
- MxA immunostaining on muscle biopsy is a sensitive and specific marker for DM, even before perifascicular atrophy develops
Autoantibody Pathogenicity
A 2024 study provided evidence that DM-specific autoantibodies may have a direct pathogenic role through internalization into muscle fibers, binding to their target antigens, and disrupting normal protein function. This effect was most pronounced for antibodies targeting proteins involved in transcriptional regulation (e.g., anti-Mi-2), which produced robust changes in muscle transcriptomic profiles. For anti-MDA5, anti-TIF1-γ, and anti-NXP-2, muscle biopsies showed a transcriptional profile predominantly restricted to IFN-β1 and IFN-β1-inducible genes.
Clinical Presentation
Cutaneous Manifestations
Skin changes are the defining feature of DM and typically precede or accompany muscle weakness. They may be the sole manifestation in clinically amyopathic DM (CADM).
| Skin Finding | Description | Clinical Significance |
|---|---|---|
| Heliotrope rash | Violaceous (purplish) discoloration of the eyelids, often with periorbital edema | Pathognomonic for DM; may be subtle in darker skin tones |
| Gottron papules | Erythematous-to-violaceous papules or plaques over the metacarpophalangeal and interphalangeal joints | Pathognomonic for DM; distinguish from SLE (which affects skin between joints) |
| Gottron sign | Macular erythematous rash over extensor surfaces of elbows, knees, and malleoli | Photosensitive distribution |
| V-sign | Erythematous rash on the anterior neck and upper chest in a V-shaped distribution | Photosensitive; worsened by sun exposure |
| Shawl sign | Erythematous rash over the posterior shoulders, upper back, and posterior neck | Distribution resembles a shawl draped over the shoulders |
| Holster sign | Erythematous rash on the lateral thighs and hips | Often overlooked; relatively specific for DM |
| Mechanic’s hands | Roughened, cracked skin on the radial and palmar aspects of the fingers | Also seen in antisynthetase syndrome; check for overlap |
| Periungual telangiectasia | Dilated capillary loops at the nail folds, sometimes with thrombi or hemorrhage | Visible on nailfold capillaroscopy; capillary dropout correlates with disease activity |
| Poikiloderma | Hyper- and hypopigmented patches on the upper back and extensor surfaces | Follows resolution of active skin lesions |
| Calcinosis cutis | Subcutaneous calcium deposits, often over pressure points (buttocks, elbows, knees) | Common in JDM (30–70%); less frequent in adults; associated with anti-NXP-2 and anti-SAE; overlying ulceration may occur |
Muscle Involvement
Muscle weakness in DM is typically symmetric, proximal greater than distal, affecting the neck flexors, shoulder girdle, and hip girdle muscles. Patients report difficulty rising from chairs, climbing stairs, lifting objects overhead, or raising the head from a pillow. Weakness may develop subacutely over days to weeks or insidiously over months. Myalgia occurs in a subset of patients. Distal weakness, when present, develops late in severe disease. Bulbar weakness with dysphagia occurs in a minority and portends a more difficult clinical course. CK is typically elevated (often 5–50× normal) but may be normal in amyopathic DM and occasionally in early disease. Aldolase may be elevated with a normal CK, serving as a marker of perimysial inflammation.
Clinically Amyopathic Dermatomyositis (CADM)
Clinically Amyopathic DM
- Definition: Characteristic DM skin findings present for ≥6 months without clinically significant muscle weakness; accounts for approximately 10–20% of DM cases
- Subtypes: Hypomyopathic DM (subclinical muscle involvement detectable on MRI, EMG, or biopsy) and amyopathic DM (no detectable muscle disease by any modality)
- Key association: Strongly linked with anti-MDA5 antibodies; these patients are at very high risk for rapidly progressive ILD despite minimal or absent muscle weakness
- Danger: CADM must not be dismissed as mild disease—pulmonary complications can be life-threatening, particularly in the anti-MDA5 subgroup
- Other subtypes: Adermatopathic DM (dermatomyositis sine dermatitis) presents with myopathy but no skin findings, leading to frequent misdiagnosis as polymyositis
Extramuscular Manifestations
- Interstitial lung disease (ILD): Occurs in 20–65% of DM patients; ranges from indolent to rapidly progressive; highest severity with anti-MDA5 antibodies; presents with dyspnea and nonproductive cough
- Cardiac: Arrhythmias, congestive heart failure, pericarditis, myocarditis; often subclinical
- Gastrointestinal: Reduced gastric motility; vasculopathy with GI ulcers, perforation, and bleeding (particularly in JDM)
- Arthritis: Nonerosive arthralgia or arthritis; may lead to flexion contractures without physical therapy
- Malignancy: 15–30% of adult DM; risk is antibody-dependent (see below)
Myositis-Specific Antibodies
Five MSAs are associated with DM. These antibodies are generally mutually exclusive and define distinct clinical phenotypes with differing prognoses, cancer risks, and treatment responses.
| Antibody | Target Antigen | Frequency | Clinical Phenotype | Cancer Risk | Prognosis |
|---|---|---|---|---|---|
| Anti-Mi-2 | NuRD complex (chromatin remodeler) | 15–20% | Classic DM: severe characteristic rash, significant proximal weakness, high CK | Mildly increased | Good; treatment-responsive |
| Anti-TIF1-γ | Transcription intermediary factor 1-gamma | 20–30% | Severe widespread rash, variable muscle weakness; often older adults | Highest (up to 60–80% in adults >40 y) | Guarded; driven by malignancy |
| Anti-NXP-2 | Nuclear matrix protein 2 | 15–25% | Moderate-to-severe weakness, dysphagia, calcinosis, subcutaneous edema; most common MSA in JDM | Increased (especially in adults) | Moderate; calcinosis may be refractory |
| Anti-MDA5 | Melanoma differentiation-associated gene 5 (RIG-I-like receptor) | 10–20% | CADM, severe skin ulceration, rapidly progressive ILD, minimal muscle involvement; higher prevalence in East Asians | Not elevated | Poor if RP-ILD develops; >50% mortality without early aggressive treatment |
| Anti-SAE | Small ubiquitin-like modifier 1 activating enzyme | 5–10% | Skin-predominant onset (may resemble CADM initially), with weakness developing later; dysphagia common | Possibly increased | Generally favorable with treatment |
Cancer Association and Screening
The association between DM and malignancy is well established, with cancer risk highest in the first 2–3 years after DM diagnosis. The risk varies significantly by antibody subtype and patient demographics.
Risk Stratification
Cancer Risk by Antibody and Clinical Features
- Highest risk: Anti-TIF1-γ positive, age >40 years → cancer prevalence up to 60–80%; ovarian, breast, lung, and GI cancers most common
- High risk: Anti-NXP-2 positive in adults (especially males >40 years); anti-SAE positive adults
- Moderate risk: Anti-Mi-2 positive adults; antibody-negative DM
- Lower risk: Anti-MDA5 positive (cancer risk not clearly elevated); juvenile DM (malignancy is rare)
- Temporal window: Most malignancies are diagnosed within 3 years of DM onset; continued surveillance is recommended during this period
- Paraneoplastic mechanism: Treatment of the underlying malignancy may improve DM symptoms, supporting a paraneoplastic relationship
IMACS 2023 Cancer Screening Guidelines
The International Myositis Assessment and Clinical Studies Group (IMACS) published the first international cancer screening guideline for idiopathic inflammatory myopathies in 2023. The framework stratifies patients into risk categories:
| Risk Level | Criteria | Screening Recommendation |
|---|---|---|
| Standard risk | DM without high-risk features; younger patients | Basic screening: age-appropriate cancer screening, chest radiography, routine labs (CBC, CMP, urinalysis) |
| Moderate risk | Adult DM without high-risk antibodies; anti-Mi-2 positive | Basic screening plus consideration of enhanced panel based on clinical suspicion |
| High risk | Anti-TIF1-γ or anti-NXP-2 positive; age >40 years; male sex; dysphagia; cutaneous necrosis; treatment-refractory disease | Enhanced screening: CT chest/abdomen/pelvis, mammography, Pap smear, colonoscopy, transvaginal ultrasound, PSA, CA-125, and consider PET scan; repeat within first 3 years |
Interstitial Lung Disease
ILD is a major cause of morbidity and mortality in DM. It occurs across antibody subtypes but is most severe and rapidly progressive with anti-MDA5 antibodies.
Anti-MDA5 Rapidly Progressive ILD
- Clinical profile: CADM with severe skin ulceration, minimal muscle weakness, ferritin markedly elevated (often >1,500 ng/mL), lymphopenia; more common in East Asian populations
- Timeline: Respiratory failure can develop within weeks to months of symptom onset; mortality exceeds 50% without early aggressive treatment
- HRCT pattern: Ground-glass opacities and consolidation, often lower lobe predominant, rapidly progressing; pneumomediastinum is an ominous sign
- Treatment: Early aggressive triple therapy is essential → high-dose corticosteroids + calcineurin inhibitor (tacrolimus or cyclosporine) + IV cyclophosphamide; plasma exchange for refractory cases
- Emerging therapies: JAK inhibitors (tofacitinib, baricitinib) have shown benefit in refractory anti-MDA5 ILD in case series; rituximab and BCMA-targeted therapies under investigation
- Monitoring: Serial ferritin levels, KL-6 (where available), PFTs, and HRCT to track response; declining ferritin correlates with clinical improvement
Diagnostic Workup
Laboratory Studies
- CK: Typically elevated (5–50× normal); may be normal in CADM; does not reliably correlate with disease severity in DM
- Aldolase: May be elevated with normal CK, suggesting perimysial pathology
- MSA panel: Send comprehensive DM antibody panel (Mi-2, TIF1-γ, NXP-2, MDA5, SAE); approximately 50–70% of DM patients will have a detectable MSA
- Myositis-associated antibodies: Anti-Ro52 is the most common; can be seen with any DM subtype and portends higher ILD risk; not specific for DM
- Additional labs: ESR, CRP, LDH, AST/ALT (with GGT to distinguish muscle from liver source), ferritin (markedly elevated in anti-MDA5 DM)
Electrodiagnostic Studies
Nerve conduction studies are typically normal. Needle EMG shows myopathic changes: fibrillation potentials reflecting active muscle fiber damage, short-duration low-amplitude polyphasic motor unit action potentials, and early recruitment. EMG is most useful for confirming myopathy, identifying an involved muscle for biopsy, and distinguishing disease relapse from steroid myopathy. A normal EMG does not exclude DM, particularly in CADM.
Muscle Biopsy
| Finding | Description | Significance |
|---|---|---|
| Perifascicular atrophy | Small, regenerating and degenerating fibers at the periphery of fascicles with increased oxidative enzyme staining | Specific for DM (also seen in antisynthetase syndrome and SLE overlap); may be absent early |
| MxA/ISG15 staining | Enhanced expression of IFN-I inducible proteins, particularly in the perifascicular region | More sensitive than perifascicular atrophy; positive before structural changes appear |
| C5b-9 on capillaries | Membrane attack complex deposition on endomysial capillaries | Relatively specific for DM; earliest detectable biopsy finding |
| Capillary changes | Reduced capillary density, endothelial hyperplasia, tubuloreticular inclusions (EM) | Reflects complement-mediated microangiopathy |
| Inflammatory infiltrate | Perivascular and perimysial: macrophages, B cells, CD4+ plasmacytoid dendritic cells | Distinct from polymyositis/IBM pattern (endomysial CD8+ T cells invading fibers) |
| MHC-I upregulation | Increased reactivity to MHC class I, especially in the perifascicular area | Nonspecific but supports inflammatory myopathy; present early |
When Can Biopsy Be Deferred?
- A positive MSA with characteristic skin findings and compatible clinical presentation may be sufficient for diagnosis without biopsy
- Biopsy remains essential when MSAs are negative, the presentation is atypical, or alternative diagnoses (muscular dystrophy, inclusion body myositis) must be excluded
- Select a mildly weak muscle for biopsy; severely weak muscles (≤3/5) may show only end-stage changes
- Open biopsy is preferred over needle biopsy in inflammatory myopathy due to the patchy nature of pathology
Imaging
- Muscle MRI: STIR sequences show muscle edema suggesting active inflammation; T1 sequences reveal fatty atrophy indicating chronic damage; useful for guiding biopsy site selection and distinguishing disease relapse from steroid myopathy
- Chest HRCT: Essential for evaluating ILD; ground-glass opacities, consolidation, and nonspecific interstitial pneumonia (NSIP) pattern are most common in DM-ILD
- PFTs: Restrictive pattern with reduced DLCO in ILD; serial monitoring tracks disease progression or treatment response
Treatment
Corticosteroids
Prednisone remains first-line immunotherapy, typically initiated at 0.75–1 mg/kg/day (usually 60 mg/day). In severe cases (significant weakness, dysphagia, dyspnea, CK in the rhabdomyolysis range), IV methylprednisolone 1 g/day for 3–5 days may be given first. Clinical improvement usually begins within 2–4 months and plateaus around 4–6 months, after which a slow taper is initiated. A reasonable taper: reduce by 10 mg every 4 weeks to 20 mg, then by 2.5–5 mg every 4 weeks to 10 mg, then by 1–2 mg every 4 weeks. Most patients require a steroid-sparing agent to minimize long-term corticosteroid toxicity.
IVIg
IVIg received the first FDA-label indication for DM based on the ProDERM trial (NEJM 2022), a double-blind, placebo-controlled study demonstrating significant improvement in muscle strength, function, and skin disease. It is now considered a first-line or early add-on therapy for DM:
- Dose: 2 g/kg divided over 2–5 days, repeated monthly for at least 3 months
- Subsequent taper by reducing dose or extending interval based on response
- Particularly useful for skin-predominant DM, patients who cannot tolerate corticosteroids, and as a bridge while steroid-sparing agents take effect
- Side effects: infusion reactions, headache, aseptic meningitis (rare), thrombotic events (rare)
Steroid-Sparing Immunosuppressants
| Agent | Dosing | Onset of Action | Key Considerations |
|---|---|---|---|
| Methotrexate | 7.5–25 mg/week (oral or SC); coadminister folic acid 1 mg/day | 4–8 weeks | Relatively rapid onset; avoid in ILD (risk of pulmonary toxicity); teratogenic; monitor LFTs, CBC |
| Azathioprine | 2–3 mg/kg/day | 4–8 months | Check TPMT genotype before starting; 10–15% develop early idiosyncratic flu-like reaction requiring permanent discontinuation; slow onset limits utility as initial agent |
| Mycophenolate mofetil | 1–3 g/day in divided doses | 3–6 months | Better tolerated than azathioprine; no hepatotoxicity; teratogenic—requires reliable contraception; useful in DM-ILD |
| Tacrolimus | 0.1–0.2 mg/kg/day in divided doses | 1–3 months | Calcineurin inhibitor; preferred add-on for anti-MDA5 ILD; monitor trough levels, renal function, electrolytes |
| Cyclosporine | 3–5 mg/kg/day in divided doses | 1–2 months | Alternative calcineurin inhibitor; more nephrotoxic with more drug interactions than tacrolimus; useful in refractory DM and DM-ILD |
| Cyclophosphamide | 0.5–1 g/m2 IV monthly | 1–3 months | Reserved for severe/refractory disease, especially rapidly progressive ILD; significant toxicity (cytopenias, hemorrhagic cystitis, infertility, malignancy risk) |
Rituximab
Rituximab (anti-CD20) is used in refractory DM, particularly in patients with positive MSAs or ILD. Although a randomized trial failed to meet its primary endpoint (attributed to study design), open-label data and registries demonstrate meaningful responses, including steroid tapering and retreatment efficacy. Typical dosing: 750 mg/m2 (up to 1 g) IV, repeated at 2 weeks, with cycles every 6–18 months based on response.
Emerging Therapies
- JAK inhibitors (tofacitinib, baricitinib, ruxolitinib): Promising in refractory cutaneous DM, JDM, and anti-MDA5 ILD; target the JAK-STAT pathway downstream of IFN-I signaling; case series and retrospective studies show benefit; prospective trials underway
- Efgartigimod (FcRn inhibitor): Phase 2/3 trial (NCT05523167) ongoing in DM, immune-mediated necrotizing myopathy, and antisynthetase syndrome
- CAR T-cell therapy: CD19-targeted CAR T cells reported effective in case reports and series for refractory inflammatory myopathies, including JDM and antisynthetase syndrome
- Apremilast (PDE-4 inhibitor): Showed benefit in recalcitrant cutaneous DM in a nonrandomized controlled trial
- Abatacept (T-cell costimulation modulator): Showed some benefit in post hoc analyses; further studies needed
Skin-Directed Therapy
For patients with mild skin-predominant disease, initial management may include strict photoprotection, topical corticosteroids or calcineurin inhibitors, and hydroxychloroquine. However, hydroxychloroquine can paradoxically worsen skin disease in a subset of DM patients (up to 30%), and patients should be counseled about this possibility.
Juvenile Dermatomyositis
Key Features of Juvenile DM
- Epidemiology: Peak onset ages 5–15 years; incidence approximately 2–4 per million children per year; female predominance (~2:1)
- Presentation: Often insidious onset with fatigue, low-grade fevers, and rash preceding weakness; anti-NXP-2 is the most common MSA in JDM
- Calcinosis: Occurs in 30–70% of JDM (far more common than in adults); associated with delayed diagnosis, prolonged disease activity, and anti-NXP-2 antibodies; deposits over pressure points may ulcerate and become infected
- GI vasculopathy: More common in JDM than adult DM; can cause GI ulcers, perforation, and hemorrhage—a major source of morbidity
- Malignancy: Extremely rare in JDM, unlike adult DM
- Treatment: Similar to adults (corticosteroids, methotrexate, IVIg); IVIg associated with highest probability of calcinosis improvement; JAK inhibitors are emerging as promising agents
- Prognosis: Generally more favorable than adult DM; early aggressive treatment reduces calcinosis risk and long-term disability; chronic continuous or polycyclic course in 40–60%
Special Considerations
Pregnancy
DM can present during pregnancy or postpartum. Disease should ideally be well controlled before conception. Safe medications include prednisone, azathioprine, and IVIg at minimum effective doses. Methotrexate, mycophenolate, and cyclophosphamide are contraindicated due to teratogenicity. Pregnancy outcomes are associated with higher rates of cesarean section, preterm birth, and low birth weight when disease is poorly controlled.
Health Disparities
Skin findings in DM may appear differently in patients with darker skin tones—the characteristic violaceous hue may present as hyperpigmented or dusky patches rather than the classic purple-red. This contributes to diagnostic delays and underrecognition. Education on the varied dermatologic presentation across skin tones is essential for timely diagnosis.
Steroid Myopathy vs. Disease Relapse
Patients on chronic corticosteroids who develop new proximal weakness pose a diagnostic challenge. Muscle MRI (STIR edema favoring relapse) and EMG (fibrillation potentials favoring relapse) help distinguish disease flare from steroid-induced myopathy. CK is typically elevated in relapse but normal in steroid myopathy. A CK that was declining and then rises again strongly suggests relapse.
Prognosis
Prognosis in DM is largely determined by antibody subtype, the presence and severity of ILD, and the presence of malignancy:
- Anti-Mi-2: Best prognosis among adult DM subtypes; treatment-responsive with sustained remission achievable in most patients
- Anti-TIF1-γ: Prognosis driven by underlying malignancy; DM may improve with cancer treatment; those without malignancy generally respond well to immunotherapy
- Anti-NXP-2: Moderate prognosis; calcinosis can be disfiguring and treatment-refractory; cancer risk requires ongoing vigilance
- Anti-MDA5: Poorest prognosis due to rapidly progressive ILD; early aggressive treatment is the strongest determinant of survival; patients who survive the initial ILD course may achieve sustained remission
- Anti-SAE: Generally favorable with treatment; skin-predominant onset may delay diagnosis but weakness typically responds to immunotherapy
Red Flags in Dermatomyositis
- Rapidly progressive dyspnea with ground-glass opacities: Consider anti-MDA5 RP-ILD → initiate triple immunosuppression immediately; do not wait for antibody results
- Markedly elevated ferritin (>1,500 ng/mL): Strongly associated with anti-MDA5 and predicts RP-ILD severity; may also indicate macrophage activation syndrome
- Skin ulceration/necrosis with minimal weakness: Characteristic of anti-MDA5 CADM; high index of suspicion for occult ILD
- Treatment-refractory DM in an adult >40 years: Reassess for occult malignancy, even if initial screening was negative; repeat enhanced screening
- New DM diagnosis in a patient >60 years: Very high cancer risk regardless of antibody status; comprehensive cancer evaluation is mandatory
- Dysphagia: May indicate severe disease; risk of aspiration pneumonia; evaluate with videofluoroscopic swallowing study; consider IVIg for rapid improvement
References
- Salajegheh MK, Amato AA. Idiopathic inflammatory myopathies. Continuum (Minneap Minn) 2025;31(5):1385–1408.
- Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of intravenous immune globulin in dermatomyositis. N Engl J Med 2022;387(14):1264–1278.
- Mammen AL, Allenbach Y, Stenzel W, Benveniste O; ENMC 239th Workshop Study Group. 239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018. Neuromuscul Disord 2020;30(1):70–92.
- Pinal-Fernandez I, Munoz-Braceras S, Casal-Dominguez M, et al. Pathological autoantibody internalisation in myositis. Ann Rheum Dis 2024;83(11):1549–1560.
- Allenbach Y, Uzunhan Y, Giraude P, et al. International guideline for idiopathic inflammatory myopathy-associated cancer screening: an IMACS initiative. Nat Rev Rheumatol 2024;20(1):57–69.
- Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57(5):664–678.
- Salajegheh M, Kong SW, Pinkus JL, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010;67(1):53–63.
- Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314(6):329–334.
- Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology 2017;88(5):493–500.
- Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65(2):314–324.
- Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76(12):1955–1964.
- Cassard L, Seraly N, Riegert M, Patel A, Fernandez AP. Dermatomyositis: practical guidance and unmet needs. Immunotargets Ther 2024;13:151–172.
- Paik JJ, Lubin G, Gromatzky A, et al. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol 2023;41(2):348–358.
- Gallay L, Fermon C, Lessard L, et al. Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis. Neurology 2022;98(21):e2108–e2119.
- Mammen AL. Paraneoplastic myopathies. Handb Clin Neurol 2024;200:327–332.